RE:Interest I would have never imagined TH could get to this rather excruciatingly low level of being ignored. I think it might be less irritating if the stock was hated rather than ignored. The good news, it probably cannot get much worse than this. Next week we will have what might be the first presentation at an investor conference this year (I can't remember another one) and we know the new IR person is looking to line up a lot of management meetings with investors. If they can keep dripping out intriguing cancer data from the phase 1b, we may see this stock return to at least some investor's radar screens.
Bucknelly21 wrote: Realistically, in your guys opinion is the only thing capable of resuscitation of the stock poc, efficacy ect. Because at this point this thing is as dead as it gets.